Clinical Trial Update: MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on MDX-010 (ipilimumab) in treating recurrent or refractory lymphoma across multiple subtypes, with the study terminated and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Chronic Lymphocytic Leukemia
• Burkitt Lymphoma
• Cutaneous B-cell Non-hodgkin Lymphoma
• Diffuse Large B-cell Lymphoma
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Intraocular Lymphoma
• Nodal Marginal Zone B-cell Lymphoma

Drugs mentioned

• MDX-010 (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2012-10-19